Accordingly, patients with a history of interstitial lung disease or pneumonitis were excluded from clinical trials of dabrafenib and trametinib combination therapy for patients with previously treated <i>BRAF</i> <sup>V600E</sup>-mutant metastatic non-small-cell lung cancer. Here, BRAF is linked to interstitial lung disease.